KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Operating Leases (2020 - 2025)

Aquestive Therapeutics has reported Operating Leases over the past 6 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Operating Leases at $4.3 million for Q4 2025, down 12.7% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (down 12.7% YoY), and the annual figure for FY2025 was $4.3 million, down 12.7%.
  • Operating Leases for Q4 2025 was $4.3 million at Aquestive Therapeutics, down from $4.5 million in the prior quarter.
  • Over the last five years, Operating Leases for AQST hit a ceiling of $6.0 million in Q2 2023 and a floor of $1.7 million in Q1 2022.
  • Median Operating Leases over the past 5 years was $5.0 million (2022), compared with a mean of $4.3 million.
  • Biggest five-year swings in Operating Leases: tumbled 35.1% in 2022 and later soared 233.68% in 2023.
  • Aquestive Therapeutics' Operating Leases stood at $1.9 million in 2021, then soared by 161.31% to $5.1 million in 2022, then grew by 6.18% to $5.4 million in 2023, then dropped by 7.98% to $5.0 million in 2024, then fell by 12.7% to $4.3 million in 2025.
  • The last three reported values for Operating Leases were $4.3 million (Q4 2025), $4.5 million (Q3 2025), and $5.2 million (Q2 2025) per Business Quant data.